Eli Lilly lowers zepbound costs with its lillydirect platform

Eli Lilly on Monday announced a new cut of the famous drug zepbound of the famous metals, in favor of access to patients and to drive the greater use of the company’s health platform, lillydirect.

Dole-dose vials of zepbound purchased through the zepbound self-pay plan on lillydirect will now cost $299 per month — down from $349 — for patients with a valid prescription.

The 5-milligram dose will also be priced at $399 per month, down from $499. All other approved doses will cost $449 per month, Eli Lilly said.

LillyDirect, established in early 2024, allows some consumers who are uninsured or underinsured or who lack adequate coverage to receive from ELI Lilly through its Zepbound Worker Tourlop program.

Trump announces to deal with drug dealers to reduce the cost of weight loss drugs

Average prices per month when not purchased through the self-pay zepbound plan are $599 milligrams for 7.5 milligrams, $1,049 milligrams, according to the pharmaceutical giant.

Wegovy, Ozempic: Barriers to accessing these weight loss drugs

The move comes less than a month after Eli Lilly announced plans to take on lower-priced Zepbound Discount Pens, although that is still subject to Food and Drug Administration (FDA) approval. Beginning in April 2026, Medicare patients will not pay more than $50 a month for zepbound sold in a mugred-dose pen and a diet pill, as long as both drugs are approved by the FDA.

Eli Lilly’s competitor Novo Nordisk makes its own weight loss drugs, Wegovy and Ozempic. (Knowing Shelby/Bloomberg via Getty Images)

For paying patients, the zepbound dose mult-dose pen will be available at the lowest dose for $299, with additional doses up to $449. When patients refill their dol-dose digital pen, they will not pay more than $449. Orforgloron will be available at the lowest dose starting at $149 with additional doses up to $399, the company that was ever mentioned.

Inths of Health Inschares Pursuing Back to Medicare Invanced by 2026

Eli Lilly and Novo Nordisk have launched their own direct platforms that aim to expand patient access by limiting new barriers to innovation. While both companies say these platforms will help new patients access their medicines, they also give each company a competitive edge.

Find FOX business on the go by clicking here

Novo Nordisk launched its platform, Novu Pharmacy, in March, allowing patients who cannot afford the standard list price or insurance coverage that does not have its weight loss drugs wegovy and ozempic.